A Phase 3 interventional study of Enlicitide Decanoate and Placebo in Hypercholesterolemia and Familial Hypercholesterolemia, sponsored by Merck Sharp & Dohme LLC. Completed at 59 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Hypercholesterolemia by Merck & Co., Inc — 1 open to participants now, 3 under way, 3 of them phase 3. Hypercholesterolemia · Merck & Co., Inc.
Among the 29 studies in Hypercholesterolemia by Merck & Co., Inc, this one is the 19th largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2023, is one of 17 in phase 3, and was the 22nd registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 29 studies in Hypercholesterolemia by Merck & Co., Inc is open now, in 1 country. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in India
Ages 18+
By country, each count listing its studies:
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 303 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 500 across the 27 interventional studies, 901 across the 2 observational. Of the 26 that completed or were terminated, 16 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
1 of the studies in Hypercholesterolemia by Merck & Co., Inc that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07821944Phase 3Merck Sharp & Dohme LLCA Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038) | 2027-11-26 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies in Hypercholesterolemia by Merck & Co., Inc, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to evaluate the efficacy, safety, and tolerability of enlicitide decanoate in adult participants with heterozygous familial hypercholesterolemia. The primary hypothesis is that enlicitide decanoate is superior to placebo on mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 24.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants received 20 mg of enlicitide decanoate orally once daily (QD) for up to 52 weeks.
Drug: Enlicitide Decanoate
Participants received enlicitide decanoate-matching placebo orally QD for up to 52 weeks.
Drug: Placebo
Oral tablet
Also known as: MK-0616
Oral tablet (placebo).
Mean Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24
Blood samples were collected at baseline and at Week 24 to determine mean percent change in LDL-C. The two treatment groups were compared using an analysis of covariance model with treatment as a fixed effect and baseline LDL-C as a covariate.
Time frame: Baseline and Week 24
Number of Participants With Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to 64 weeks (8 weeks postdose)
Number of Participants Who Discontinued Study Drug Due to an AE
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to 56 weeks
Mean Percent Change From Baseline in LDL-C at Week 52
Blood samples were collected at baseline and at Week 52 to determine mean percent change in LDL-C. The two treatment groups were compared using an analysis of covariance model with treatment as a fixed effect and baseline LDL-C as a covariate.
Time frame: Baseline and Week 52
Mean Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (HDL-C) at Week 24
Blood samples were collected at baseline and at Week 24 to determine mean percent change in non-HDL-C. The two treatment groups were compared using an analysis of covariance model with treatment as a fixed effect and baseline non-HDL-C as a covariate.
Time frame: Baseline and Week 24
Mean Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 24
Blood samples were collected at baseline and at Week 24 to determine mean percent change in ApoB. The two treatment groups were compared using an analysis of covariance model with treatment as a fixed effect and baseline ApoB as a covariate.
Time frame: Baseline and Week 24
Percent Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 24
Blood samples were collected at baseline and at Week 24 to determine percent change in Lp(a). For percent change in Lp(a) at Week 24, the two treatment groups were analyzed using the Wilcoxon signed rank test with Hodges-Lehmann estimation.
Time frame: Baseline and Week 24
Percentage of Participants With LDL-C <70 mg/dL and ≥50% Reduction From Baseline at Week 24
Blood samples were collected at baseline and at Week 24 to determine the percentage of participants who had LDL-C \<70 mg/dL and ≥50% reduction from baseline. The two treatment groups were analyzed based on the Miettinen and Nurminen method for the difference in percentage.
Time frame: Baseline and Week 24
Percentage of Participants With LDL-C <55 mg/dL and ≥50% Reduction From Baseline at Week 24
Blood samples were collected at baseline and at Week 24 to determine the percentage of participants who had LDL-C \<55 mg/dL and ≥50% reduction from baseline. The two treatment groups were analyzed based on the Miettinen and Nurminen method for the difference in percentage.
Time frame: Baseline and Week 24
| Milestone | Enlicitide Decanoate | Placebo |
|---|---|---|
| Started | 202 | 101 |
| Completed | 196 | 97 |
| Not completed | 6 | 4 |
| Withdrew: Withdrawal by subject | 5 | 3 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Death | 1 | 0 |
Blood samples were collected at baseline and at Week 24 to determine mean percent change in LDL-C. The two treatment groups were compared using an analysis of covariance model with treatment as a fixed effect and baseline LDL-C as a covariate.
| Percent Change | Enlicitide Decanoate | Placebo |
|---|---|---|
| Mean Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24 | -58.2 ± 28.0 | 2.6 ± 23.6 |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Participants | Enlicitide Decanoate | Placebo |
|---|---|---|
| Number of Participants With Adverse Events (AEs) | 157 | 77 |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Participants | Enlicitide Decanoate | Placebo |
|---|---|---|
| Number of Participants Who Discontinued Study Drug Due to an AE | 4 | 3 |
Blood samples were collected at baseline and at Week 52 to determine mean percent change in LDL-C. The two treatment groups were compared using an analysis of covariance model with treatment as a fixed effect and baseline LDL-C as a covariate.
| Percent Change | Enlicitide Decanoate | Placebo |
|---|---|---|
| Mean Percent Change From Baseline in LDL-C at Week 52 | -55.3 ± 27.9 | 8.7 ± 33.0 |
Blood samples were collected at baseline and at Week 24 to determine mean percent change in non-HDL-C. The two treatment groups were compared using an analysis of covariance model with treatment as a fixed effect and baseline non-HDL-C as a covariate.
| Percent Change | Enlicitide Decanoate | Placebo |
|---|---|---|
| Mean Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (HDL-C) at Week 24 | -52.3 ± 26.9 | 2.1 ± 20.5 |
Blood samples were collected at baseline and at Week 24 to determine mean percent change in ApoB. The two treatment groups were compared using an analysis of covariance model with treatment as a fixed effect and baseline ApoB as a covariate.
| Percent Change | Enlicitide Decanoate | Placebo |
|---|---|---|
| Mean Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 24 | -48.2 ± 23.6 | 1.8 ± 17.5 |
Blood samples were collected at baseline and at Week 24 to determine percent change in Lp(a). For percent change in Lp(a) at Week 24, the two treatment groups were analyzed using the Wilcoxon signed rank test with Hodges-Lehmann estimation.
| Percent Change | Enlicitide Decanoate | Placebo |
|---|---|---|
| Percent Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 24 | -24.7 (-78.1 to 170.6) | -1.6 (-47.4 to 67.0) |
Blood samples were collected at baseline and at Week 24 to determine the percentage of participants who had LDL-C \<70 mg/dL and ≥50% reduction from baseline. The two treatment groups were analyzed based on the Miettinen and Nurminen method for the difference in percentage.
| Percentage of Participants | Enlicitide Decanoate | Placebo |
|---|---|---|
| Percentage of Participants With LDL-C <70 mg/dL and ≥50% Reduction From Baseline at Week 24 | 70.8 | 1.0 |
Blood samples were collected at baseline and at Week 24 to determine the percentage of participants who had LDL-C \<55 mg/dL and ≥50% reduction from baseline. The two treatment groups were analyzed based on the Miettinen and Nurminen method for the difference in percentage.
| Percentage of Participants | Enlicitide Decanoate | Placebo |
|---|---|---|
| Percentage of Participants With LDL-C <55 mg/dL and ≥50% Reduction From Baseline at Week 24 | 67.3 | 1.0 |
Collected over Up to 64 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Enlicitide Decanoate | 1/202 (0.5%) | 9/202 (4.5%) | 102/202 (50.5%) |
| Placebo | 0/101 (0%) | 4/101 (4%) | 43/101 (42.6%) |
| Event | Enlicitide Decanoate | Placebo |
|---|---|---|
| PneumoniaInfections and infestations | 4/202 | 0/101 |
| Angina pectorisCardiac disorders | 0/202 | 1/101 |
| Secondary adrenocortical insufficiencyEndocrine disorders | 0/202 | 1/101 |
| HaemorrhoidsGastrointestinal disorders | 0/202 | 1/101 |
| Oral infectionInfections and infestations | 0/202 | 1/101 |
| Device dislocationProduct Issues | 0/202 | 1/101 |
| Hypertensive crisisVascular disorders | 0/202 | 1/101 |
| DeathGeneral disorders | 1/202 | 0/101 |
| CholelithiasisHepatobiliary disorders | 1/202 | 0/101 |
| Hand fractureInjury, poisoning and procedural complications | 1/202 | 0/101 |
| Event | Enlicitide Decanoate | Placebo |
|---|---|---|
| COVID-19Infections and infestations | 8/202 | 11/101 |
| NasopharyngitisInfections and infestations | 19/202 | 8/101 |
| InfluenzaInfections and infestations | 17/202 | 9/101 |
| NauseaGastrointestinal disorders | 16/202 | 7/101 |
| Accidental overdoseInjury, poisoning and procedural complications | 16/202 | 4/101 |
| HeadacheNervous system disorders | 16/202 | 7/101 |
| DiarrhoeaGastrointestinal disorders | 15/202 | 2/101 |
| DizzinessNervous system disorders | 14/202 | 4/101 |
| Upper respiratory tract infectionInfections and infestations | 10/202 | 6/101 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 6/202 | 6/101 |
| Age, Continuous(Years) | Enlicitide Decanoate | Placebo | Total |
|---|---|---|---|
| Mean | 52.9 ± 13.4 | 51.4 ± 13.9 | 52.4 ± 13.5 |
| Sex: Female, Male(Participants) | Enlicitide Decanoate | Placebo | Total |
|---|---|---|---|
| Female | 108 | 47 | 155 |
| Male | 94 | 54 | 148 |
| Ethnicity (NIH/OMB)(Participants) | Enlicitide Decanoate | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 40 | 24 | 64 |
| Not Hispanic or Latino | 156 | 73 | 229 |
| Unknown or Not Reported | 6 | 4 | 10 |
| Race (NIH/OMB)(Participants) | Enlicitide Decanoate | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 31 | 19 | 50 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 8 | 1 | 9 |
| White | 144 | 67 | 211 |
| More than one race | 19 | 14 | 33 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Baseline Low-density Lipoprotein Cholesterol (LDL-C)(mg/dL) | Enlicitide Decanoate | Placebo | Total |
|---|---|---|---|
| Mean | 120.7 ± 38.2 | 115.6 ± 46.1 | 119.0 ± 41.0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Aug 2023 to primary completion in Apr 2025, 19 months.
Results were first posted in Feb 2026, 10 months after primary completion.
Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 19 months is close to that.
Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MK-0616